Stable Gastric Pentadecapeptide BPC 157—Possible Novel Therapy of Glaucoma and Other Ocular Conditions [PDF]
Pharmaceuticals, 2023 Recently, stable gastric pentadecapeptide BPC 157 therapy by activation of collateral pathways counteracted various occlusion/occlusion-like syndromes, vascular, and multiorgan failure, and blood pressure disturbances in rats with permanent major vessel ...
Predrag Sikiric +23 more
doaj +2 more sources
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing [PDF]
Frontiers in Pharmacology, 2021 Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy ...
Sven Seiwerth +23 more
doaj +2 more sources
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats [PDF]
Biomedicines, 2021 (1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2)
Mladen Japjec +17 more
doaj +2 more sources
Pentadecapeptide BPC 157 and the central nervous system [PDF]
Neural Regeneration Research, 2022 We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157, three very recent demonstrations that may be essential in the gut-brain and brain-gut axis operation, and therapy application in the central nervous system ...
Jakša Vukojevic +11 more
doaj +2 more sources
BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling “Negative-Like” Symptoms of Schizophrenia [PDF]
Biomedicines, 2022 We attempted throughout the NO-system to achieve the particular counteraction of the ketamine-induced resembling “negative-like” schizophrenia symptoms in rats using pentadecapeptide BPC 157, and NO-agents, NG-nitro-L-arginine methylester (L-NAME), and ...
Andrea Zemba Cilic +18 more
doaj +2 more sources
Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy [PDF]
Pharmaceuticals, 2023 Even before behavioral disturbances, neuroleptics, amphetamine, and domperidone application rapidly emerged severe occlusion/occlusion-like syndrome, shared innate vascular and multiorgan failure in rats, comparable to occlusion/occlusion-like syndrome ...
Sanja Strbe +20 more
doaj +2 more sources
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats [PDF]
PharmaceuticalsBackground/Objectives: This 7-day rat tracheocutaneous fistula study considered the not-studied issues of tracheocutaneous fistula course, wound healing, and fistula in the NO-system relations.
Goran Madzarac +22 more
doaj +2 more sources
Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle [PDF]
Biomedicines, 2022 First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and ...
Mario Staresinic +24 more
doaj +2 more sources
Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review [PDF]
PharmaceuticalsBPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory
Michalina Józwiak +3 more
doaj +2 more sources
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy [PDF]
Pharmaceuticals, 2023 We focused on the first demonstration that antiarrhythmics, particularly class II and class III antiarrhythmic and beta-blocker sotalol can induce severe occlusion/occlusion-like syndrome in rats.
Ivica Premuzic Mestrovic +23 more
doaj +2 more sources